A Pivotal Study of BPP-1001 in Patients with Post-Concussion Syndrome (PCS) whose Symptoms of Neuroinflammation have Remained Unresolved

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 31 Oct 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BPP 1001 (Primary)
Indications Postconcussional syndrome
Focus Registrational; Therapeutic Use
Sponsors Bioscience Pharma Partners

Most Recent Events

31 Oct 2018 New trial record
24 Oct 2018 According to a Bioscience Pharma Partners (BPP) media release, this study is scheduled for H1 2019, following which BPP will actively seek breakthrough therapy status for the compound.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight